ZTS

Zoetis Inc
NYSEHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

Key Statistics

Market Cap
$29.36B
P/E Ratio
11.59
EPS
$6.13
Beta
0.73
52W High
$145.99
52W Low
$69.52
50-Day MA
$75.04
200-Day MA
$99.79
Dividend Yield
2.93%
Profit Margin
27.70%
Forward P/E
11.99
PEG Ratio
6.66

About Zoetis Inc

Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$9.53B
Gross Profit (TTM)$6.83B
EBITDA$4.07B
Operating Margin40.70%
Return on Equity64.90%
Return on Assets15.30%
Revenue/Share (TTM)$22.14
Book Value$7.84
Price-to-Book9.40
Price-to-Sales (TTM)3.08
EV/Revenue3.901
EV/EBITDA9.25
Quarterly Earnings Growth (YoY)1.20%
Quarterly Revenue Growth (YoY)-0.20%
Shares Outstanding$413.22M
Float$412.37M
% Insiders0.16%
% Institutions99.99%

Historical Volatility

HV 10-Day
22.44%
HV 20-Day
22.63%
HV 30-Day
28.13%
HV 60-Day
30.91%
HV Rank
44.4%

Volatility is currently contracting

Analyst Ratings

Consensus ($96.00 target)
4
Strong Buy
5
Buy
9
Hold

Latest News

Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive Vice President, Chief Financial Officer and Chief Operating Officer Jay Saccaro will review third quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://in.

Business Wire9/24/2026Neutral
Zoetis: The Worst May Be Priced In

Zoetis faces ongoing headwinds but is now considered a cautious 'Buy' as valuation reflects low-to-mid single-digit growth potential. Q2 results disappointed, with flat revenues and declining U.S. sales, but international and livestock segments showed resilience and growth. Management revised 2026 guidance downward, but ZTS's low valuation multiples and aggressive share buybacks support its fair value case.

Seeking Alpha9/18/2026Negative
Zoetis: An Undervalued Compounder Hiding In Plain Sight

Zoetis is rated a buy, as I see current headwinds as temporary and the stock undervalued based on my DCF valuation. ZTS faces near-term pressure from weaker U.S. companion animal demand, increased competition, and margin compression due to promotions and rebates. Long-term growth is supported by structural pet humanization trends, international expansion, a robust R&D pipeline, and a growing diagnostics segment.

Seeking Alpha9/17/2026Positive
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 1:50 p.m. ET. Interested parties can access the live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be ava.

Business Wire9/2/2026Neutral
Zoetis: A Solid Long-Term Buy After Harsh Drawdown

Zoetis is navigating the worst drawdown in its stock history, driven by weakening U.S. vet clinic traffic and heightened competition across key companion animal franchises. Despite aggressive competitor promotions, Zoetis protects industry-leading profitability (35%–37% EBIT margins) using targeted gross-to-net rebates rather than base list-price cuts. Trading at a historic low 12x P/E and a 7%+ FCF yield, Zoetis offers a strong margin of safety compared to its Base Case DCF fair value of $100.06.

Seeking Alpha8/18/2026Positive
Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense

Zoetis (ZTS) now trades at just 12x forward earnings, with a nearly 3% dividend yield and gross margins above 70%, after a severe multiyear drawdown. Competition, weaker U.S. companion animal sales, and reduced guidance have pressured ZTS, but its core profitability and market dominance remain intact. Management is aggressively repurchasing shares, capital returns are strong, and the balance sheet remains healthy despite $9B in long-term debt.

Seeking Alpha8/14/2026Positive

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ZTS and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/26/2026